04 March 2026
04 March 2026
New drugs and lucrative markets in the US remain crucial to Europe’s pharma sector, as governments approach closer trade with Asia.
While some chief executives have left for personal reasons, others have been ousted amid poor company performance.
OSE will now pivot to focus on the late-stage development of its cancer vaccine, Tedopi and its anti-inflammatory drug, lusvertikimab.
The agreement will see Esperion, via a subsidiary, purchase all outstanding stock of Corstasis for an upfront cash payment of $75m.
Aspire Biopharma’s new sublingual powder bypasses digestion, delivering alprazolam directly for faster anxiety and panic relief.
The combined cash balance at closing is projected to fund operations through 2030.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
